Elevated Soluble Galectin-3 as a Marker of Chemotherapy Efficacy in Breast Cancer Patients: A Prospective Study.
Journal
International journal of breast cancer
ISSN: 2090-3170
Titre abrégé: Int J Breast Cancer
Pays: Egypt
ID NLM: 101568103
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
03
2019
revised:
25
01
2020
accepted:
25
02
2020
entrez:
2
4
2020
pubmed:
2
4
2020
medline:
2
4
2020
Statut:
epublish
Résumé
Galectin-3 (Gal-3) is a glycan-binding lectin with a debated role in cancer progression due to its various functions and patterns of expression. The current study investigates the relationship between breast cancer prognosis and secreted Gal-3. Breast cancer patients with first time cancer diagnosis and no prior treatment ( Enhanced levels of plasma (adjuvant) and stromal (neoadjuvant) Gal-3 were found to be markers of chemotherapy efficacy. The patients with chemotherapy-induced increase in extracellular Gal-3 had longer disease-free interval and significantly lower rate of recurrence during 84-month follow-up compared to patients with unchanged or decreased secretion. The findings support the use of plasma Gal-3 as a marker for chemotherapy efficacy when no residual tumor is visible through imaging. Furthermore, stromal levels in any remaining tumors postchemotherapy can also be used to predict long-term prognosis in patients.
Identifiants
pubmed: 32231800
doi: 10.1155/2020/4824813
pmc: PMC7097759
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4824813Informations de copyright
Copyright © 2020 Arooj Shafiq et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
PLoS One. 2012;7(8):e42699
pubmed: 22900040
Breast Cancer Res. 2016 Sep 29;18(1):97
pubmed: 27687248
Med Sci Monit. 2015 Mar 13;21:755-60
pubmed: 25765552
Clin Chim Acta. 2014 Apr 20;431:185-91
pubmed: 24530298
J Biol Chem. 2004 Oct 29;279(44):46104-12
pubmed: 15319436
J Nucl Med. 2016 Feb;57 Suppl 1:53S-9S
pubmed: 26834103
Clin Chem. 2017 Mar;63(3):691-699
pubmed: 28073896
Pathol Res Pract. 2017 Apr;213(4):348-352
pubmed: 28215640
Indian J Radiol Imaging. 2016 Oct-Dec;26(4):475-481
pubmed: 28104942
Mol Cancer Res. 2009 Oct;7(10):1655-62
pubmed: 19825987
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
Breast Cancer Res Treat. 2006 Nov;100(2):229-35
pubmed: 16932852
Clin Cancer Res. 2000 Apr;6(4):1389-93
pubmed: 10778968
Clin Biochem. 2017 Jul;50(10-11):599-604
pubmed: 28322756
J Pathol. 2009 May;218(1):66-75
pubmed: 19199318
Ann Oncol. 2012 Sep;23 Suppl 10:x231-6
pubmed: 22987968
Cancer Cell Int. 2018 Nov 3;18:172
pubmed: 30410421
PLoS One. 2014 Sep 25;9(9):e103482
pubmed: 25254965
BMC Cancer. 2016 Aug 15;16:636
pubmed: 27526676
J Clin Oncol. 2007 Oct 1;25(28):4414-22
pubmed: 17785706
Oncogene. 2006 Dec 7;25(58):7650-61
pubmed: 17043663
PLoS One. 2011;6(6):e20859
pubmed: 21698183
Cancer Res. 2006 Mar 15;66(6):3114-9
pubmed: 16540661
J Med Invest. 2008 Feb;55(1-2):127-32
pubmed: 18319555
Medicine (Baltimore). 2016 Feb;95(8):e2914
pubmed: 26937935
Anticancer Res. 2006 Mar-Apr;26(2B):1369-76
pubmed: 16619546
Cancer Res. 2003 Dec 1;63(23):8302-11
pubmed: 14678989
Gastroenterology. 2018 Apr;154(5):1524-1537.e6
pubmed: 29274868
Clin Cancer Res. 2020 Jan 22;:
pubmed: 31969339
J Pathol. 1996 May;179(1):43-8
pubmed: 8691344